Ligand Pharmaceuticals (LGND) Non-Current Deffered Revenue (2010 - 2024)

Ligand Pharmaceuticals has disclosed Non-Current Deffered Revenue across 12 years of filings, most recently posting $2.2 million for Q4 2024.

• Non-Current Deffered Revenue for Q4 2024 came in at $2.2 million, up 55.54% year-over-year; the trailing twelve-month figure through Dec 2024 was $2.2 million (up 55.54% YoY), and the FY2024 annual result was $2.2 million, up 55.54% from the prior year.
• Non-Current Deffered Revenue came in at $2.2 million for Q4 2024 at Ligand Pharmaceuticals, down from $2.5 million in the prior quarter.
• In the past five years, Non-Current Deffered Revenue ranged from a high of $9.3 million in Q4 2021 to a low of $44000.0 in Q4 2022.
• The 4-year median for Non-Current Deffered Revenue is $2.7 million (2024), against an average of $3.8 million.
• Across the five-year window, Non-Current Deffered Revenue slumped 99.53% in 2022 and soared 3181.82% in 2023, its largest moves.
• Ligand Pharmaceuticals' Non-Current Deffered Revenue stood at $9.3 million in 2021, then plunged by 99.53% to $44000.0 in 2022, then jumped by 3181.82% to $1.4 million in 2023, then jumped by 55.54% to $2.2 million in 2024.
• The last three Non-Current Deffered Revenue figures came in at $2.2 million (Q4 2024), $2.5 million (Q3 2024), and $2.7 million (Q2 2024), per Business Quant data.